Southwark medical imaging specialist wins £1m European biopharmaceutical contract

IXICO PLC, the Southwark based medical imaging advanced analytics company, has announced its selection to provide PET and MRI imaging services to a leading European biopharmaceutical company specialising in neurodegenerative conditions.

The sponsor is a new client for IXICO, and this trial will run over approximately five years. This study will include participants with Alzheimer’s disease (AD) as well as participants with Down Syndrome.

IXICO is providing end to end support to the sponsor for this trial: from consultation in planning and design of the imaging protocols to the set up and management of imaging centres, collection and control of imaging data (including Amyloid and Tau PET), radiology and subsequent analysis and reporting of data.

Having built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders, IXICO is able to provide advanced neuroimaging solutions and services from Phase I through to commercialisation.

Giulio Cerroni, CEO of IXICO, commented: “We are delighted to be awarded this contract. Our success in being awarded this study with another new client follows on from our success in securing contracts with nine new clients during the last financial year and is a further contract that utilises both our MRI and PET service portfolios.

“Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders, and this contract reflects the confidence that increasing numbers of companies are placing in IXICO as their trusted neuroimaging partner for their important CNS studies.”